Lymphoma, Mixed-Cell
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
Track Lymphoma, Mixed-Cell automatically
Every clearance here is in the API, with alerts when new ones post.